Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bamocaftor (Primary) ; Ivacaftor/tezacaftor (Primary) ; Ivacaftor/tezacaftor/VX-659 (Primary) ; Deutivacaftor; Ivacaftor; Tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals

    • Most Recent Events

    • 18 Oct 2018 According to a Vertex Pharmaceuticals media release, primary endpoint (Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)) has been met.
    • 18 Oct 2018 According to a Vertex Pharmaceuticals Media Release, data presented at North American Cystic Fibrosis Conference (NACFC).
    • 18 Oct 2018 Results presented in a Vertex Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top